Bio Pharma

Teduglutide (API) to accelerate Loose bowl syndrome therapy

Background

  • Teduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome. 
  • It works by promoting mucosal growth and possibly restoring gastric emptying and secretion.
  • Our technology on Teduglutide would benefit many pharma majors to decrease their cost of peptides production.

Salient features Lorven’s Teriparatide

  • Application ready Teduglutide Biosimilar from E. coli.
  • High pure (96%), available at an economical price .
  • Lorven’s Teduglutide is expressed in E. coli expression system.
  • Yields up to gm/lit/hour.
  • Reduced production cost and speed time to market.
  • Product Quality

  • Biosimilar to Teriparatide (Novo Nordisk).
  • 100% native confirmation.
  • Functionally active peptide.
  • Free from animal-derived components.

Safety

  • E. coli : Genetically highly amenable host organism with BSL-1 maintenance.

IP

  • Patent Application Under process:
  • Title: Process for improved expression of biologically active Teduglutide in E. coli expression system by strain engineering.